^
    Back
    Association details:
    Biomarker:CXCL13 elevation
    Cancer:Chronic Lymphocytic Leukemia
    Drug:Imbruvica (ibrutinib) (BTK inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Leukemia
    Title:

    CXCL13 plasma levels function as a biomarker for disease activity in patients with chronic lymphocytic leukemia

    Published date:
    10/21/2020
    Excerpt:
    We analyzed CXCL13 plasma concentrations in 400 CLL patients...elevated CXCL13 plasma levels normalized during ibrutinib therapy, and increased in ibrutinib resistance patients.
    DOI:
    10.1038/s41375-020-01063-7